Trinity Biotech, PulseAI Form Strategic Collaboration

Trinity Biotech plc is teaming up with medical artificial intelligence (AI) firm PulseAI to enhance its recently acquired continuous glucose monitor (CGM) biosensor technology.

Under the collaboration, Trinity Biotech will provide a pool of multi-parameter CGM datasets from its existing biosensor database to PulseAI. The data will be used to help design and implement Trinity Biotech’s AI-driven health and wellness analytics platform, which is a key component of Trinity Biotech’s CGM solution. The company is aiming to differentiate its affordable, needle-free and reusable diabetes management solution in preparation for its global launch.

“This collaboration will deliver important insights as we develop our AI driven analytical platform. This project will harness the potential of using additional personalised data from in, on and around the body to enhance the utility of continuous glucose measurements, improving the user experience, increasing satisfaction, and providing superior metabolic insights,” Trinity Biotech Chief Technology Officer Dr Gary Keating stated.

“We’re delighted to partner with Trinity Biotech on this project which should result in the development of powerful data analytics, and lay the groundwork for future innovation and exploration in the context of glucose monitoring and broader health analytics,” PulseAI CEO Alan Kennedy said. 

Trinity Biotech is a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. The company develops, acquires, manufactures, and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. It has entered the wearable biosensor industry with the acquisition of the biosensor assets of Waveform Technologies Inc.; the company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K., and through a network of international distributors and strategic partners in more than 75 countries worldwide. 

PulseAI is a medical technology company based in Belfast, Northern Ireland. The company builds AI-enabled software products designed to improve the accuracy, efficiency and scalability of cardiac diagnostics. Developed on a growing proprietary database of more 6 million ECGs recorded from 2 million patients, PulseAI has created a cloud-based platform allowing for easy device integration and scalable deployment of deep learning AI-ECG algorithms.